Last reviewed · How we verify

NCT04822792: PRESCIENT

Pan-canceR Early-Stage deteCtion by lIquid Biopsy tEchNique projecT

Status unknown Last updated 2 June 2021
What this trial tests

trial testing Multi-cancer early detection test in Cancer in 11,879 participants. Status unknown.

Timeline
23 March 2021
Primary endpoint
31 March 2023
30 June 2023

Quick facts

Lead sponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment11,879
Start date23 March 2021
Primary completion31 March 2023
Estimated completion30 June 2023
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Who can join

Adults 40 to 75, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PRESCIENT is a multi-center, prospective observational study aimed to detect cancers early by combined assays for serum protein markers and cell-free DNA (cfDNA) methylation markers. Blood RNA markers will also be evaluated. The study will enroll approximately 11879 participants, including participants with malignancies or benign diseases, and healthy participants.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests.
    Brito-Rocha T, Constâncio V, Henrique R, Jerónimo C. · · 2023 · cited 72× · PMID 36980276 · DOI 10.3390/cells12060935
  2. Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.
    Imai M, Nakamura Y, Yoshino T. · · 2025 · cited 15× · PMID 39799530 · DOI 10.1007/s10147-025-02694-5
  3. Current and emerging applications of liquid biopsy in pan-cancer.
    Wang W, He Y, Yang F, Chen K. · · 2023 · cited 12× · PMID 37315508 · DOI 10.1016/j.tranon.2023.101720
  4. Utilizing Plasma Circulating Tumor DNA Sequencing for Precision Medicine in the Management of Solid Cancers.
    Cha Y, Kim S, Han SW. · · 2023 · cited 10× · PMID 36915241 · DOI 10.4143/crt.2023.446
  5. Cancer Screening: Present Recommendations, the Development of Multi-Cancer Early Development Tests, and the Prospect of Universal Cancer Screening.
    Galeș LN, Păun MA, Anghel RM, Trifănescu OG. · · 2024 · cited 9× · PMID 38539525 · DOI 10.3390/cancers16061191
  6. Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer.
    Gianni C, Palleschi M, Merloni F, Bleve S, et al · · 2022 · cited 4× · PMID 36612091 · DOI 10.3390/cancers15010096
  7. Multicancer Early Detection Tests: A State-of-the-Art Review for Otolaryngologists.
    Kennedy E, Durm G, Farlow JL. · · 2024 · cited 2× · PMID 39463807 · DOI 10.1002/oto2.70040
  8. Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study.
    Duan J, Gao Q, Wang Z, Xu J, et al · · 2026 · cited 1× · PMID 41737326 · DOI 10.1016/j.xinn.2025.101076

Verify or expand the search:

Other trials of Multi-cancer early detection test

Trials testing the same drug.

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04822792.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing